Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL (2003). The use of growth factors in the treatment of
chronic diabetic foot ulcers. Br J Surg 90:133-146.
Ellis IR, Jones SJ, Staunton D, Vakonakis I, Norman
DG, Potts JR, Milner CM, Meenan NA, Raibaud S, Ohea G, Schor AM, Schor SL
(2010a). Multi-factorial modulation of IGD motogenic
potential in MSF (migration stimulating factor). Exp Cell
Kay RA, Ellis IR, Jones SJ, Perrier S, Florence M,
Schor AM, Schor SL (2005). The
expression of MSF, a potent onco-fetal cytokine, is uniquely controlled by
3'UTR-dependent nuclear sequestration of its precursor mRNA. Cancer
Res. 65: 10742-10749.
Keatch RP. Schor AM, Vorstius JB, Schor SL (2012). Biomaterials in regenerative medicine: engineering to recapitulate the
natural. Current Opinion in
Schor A.M, Schor SL (2010). Angiogenesis and tumour
progression: migration-stimulating factor as a novel target for clinical
intervention. Eye. 24:450-458.
Schor SL, Ellis I, Banyard J, Schor AM (1999). Motogenic
activity of the IGD amino acid motif. J Cell Sci. 112:3879-3888.
Schor SL, Ellis IR, Jones SJ, Baillie R, Seneviratne K, Clausen J, Motegi K,
Vojtesek B, Kankova K, Furrie E, Sales
MJ, Schor AM, Kay RA (2003). Migration Stimulating Factor (MSF): A
genetically-truncated fibronectin isoform expressed by carcinoma and
tumor-associated stromal cells. Cancer
Schor SL, Ellis IR, Jones SJ, Woolston AM, Schor AM. (2012) Bi-stable
epigenetic switch in MSF expression is regulated by the concerted signalling of
TGF-beta1 and the extracellular matrix.. Int J Cancer. 130:2024-2032.
Schor SL, Schor AM, Keatch RP, Belch JJF
(2005). Role of matrix macromolecules in
the aetiology and treatment of chronic ulcers. In The Wound Management Manual (ed. BY Lee). McGraw Hill, New York. pp109-121.
Shpiro N, Ellis IR, Dines TJ, Schor AM, Schor SL, Norman DG, Marquez R (2005).
Synthesis of an IGD peptidomometic with motogenic activity. Mol Biosystems 1:318-320.
Vakonakis I, Staunton D,
Ellis IR, Sarkies P, Flanagan A, Schor AM, Schor SL, Campbell ID (2009).
Motogenic sites in human fibronectin are masked by long range
interactions. J. Biol. Chem.